Evidence map›Paper›PMID 36224254›Full record

ArticleScientific reports2022

Design, synthesis and computational study of new benzofuran hybrids as dual PI3K/VEGFR2 inhibitors targeting cancer.

Omar A El-Khouly, Morkos A Henen, Magda A-A El-Sayed, Shahenda M El-Messery

Abstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Design, synthesis, andRSC advances · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Omar A El-KhoulyDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, P.O. Box 35516, Mansoura, Egypt.
Morkos A HenenDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, P.O. Box 35516, Mansoura, Egypt.
Magda A-A El-SayedDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, P.O. Box 35516, Mansoura, Egypt.
Shahenda M El-MesseryDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Mansoura University, P.O. Box 35516, Mansoura, Egypt. habib2001@mans.edu.eg.

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
600 MHz NMR console and cold probeS10OD025020 · OD · UNIVERSITY OF COLORADO DENVER · PI JONES, DAVID NIGEL · 2018 to 2018
$501k
Small molecule inhibitors targeting the SARS-CoV-2 pathogenicity factor Nsp1R21AI171827 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HENEN, MORKOS, STECKELBERG, ANNA-LENA · 2022 to 2023
$458k
NCI NIH HHS P30 CA046934NIAID NIH HHS R21 AI171827NIH HHS S10 OD025020
6 · The paper itself

Abstract

Design and synthesis of a new series of benzofuran derivatives has been performed.

Indexed as

Antineoplastic AgentsBenzofuransBreast NeoplasmsUterine Cervical NeoplasmsCell ProliferationDrug DesignDrug Screening Assays, AntitumorFemaleHumansMCF-7 CellsMolecular Docking SimulationMolecular StructurePhosphatidylinositol 3-KinasesProtein Kinase InhibitorsSorafenibStructure-Activity RelationshipAntineoplastic AgentsBenzofuransPhosphatidylinositol 3-KinasesProtein Kinase InhibitorsSorafenibVascular Endothelial Growth Factor Receptor-2

Identifiers

PMID36224254
PMCPMC9556824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.